Carbohydrate antigen 19-9 (CA19-9) evaluation through a novel method significantly predicts overall and disease-free survival in borderline resectable pancreatic adenocarcinoma patients undergoing neoadjuvant therapy. A study with 991 participants revealed that those with a mean Δf below defined thresholds demonstrated significantly improved prognoses, associating with hazard ratios for overall survival of 0.6 and 0.4 for negative and positive slope coefficients, respectively. This innovative approach offers clinicians an essential tool for personalized treatment strategies.
Journal Article by Garnier J, Marchetti A (…) Javed AA et 19 al. in Ann Surg
Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc.